Scholarlink

Background <p>Male breast cancer (BC) is a rare entity and represents a significant clinical challenge due to its late diagnosis and resulting poorer prognosis compared to female BC. As shown by prior studies, approximately 99% of male BC patients are hormone receptor-positive (HR +). This study aimed to evaluate the utilization and impact of adjuvant endocrine therapy (ET) in male early BC patients using a large German real-world claims dataset.</p> Patients and methods <p>Data were collected from a major German statutory health insurance provider (AOK Baden-Wuerttemberg) covering the period between January 1, 2010, and December 31, 2020. Male patients diagnosed with early BC who underwent breast surgery were included. ET use was determined by prescription records. The impact of ET on overall survival (OS) was assessed using univariable (log-rank) and multivariable (cox regression) analysis.</p> Results <p>Among 128 male early BC patients, 16% (<i>n</i> = 21) did not utilize adjuvant ET. On univariable analysis, ET was significantly associated with 5-year OS (74% with ET vs. 37% without ET; <i>p</i> &lt; 0.0001). Multivariable analysis revealed ET use (Hazard Ratio [HR]: 0.31, 95% CI 0.14–0.69, <i>p</i> = 0.004) having a positive effect on OS, whereas age (HR: 1.04, 95% CI 1.00–1.09) and comorbidities (HR: 1.18, 95% CI 1.05–1.34, <i>p</i> = 0.007) were identified as negative predictive factors for OS.</p> Conclusion <p>A significant proportion of male patients with early BC does not use ET. However, the use of ET plays a key role in improving survival outcomes for male patients with early BC. Efforts to improve the use of ET, including patient education and management of side effects, are essential to optimize treatment outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of adjuvant endocrine therapy utilization in male patients with early breast cancer: results from a large German real-world claims data analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月17日

查看全文
  • Dominik Dannehl,
  • Tjeerd Maarten Hein Dijkstra,
  • Alexandra von Au,
  • Anna Sophie Scholz,
  • Léa Louise Volmer,
  • Markus Hahn,
  • Sabine Hawighorst-Knapstein,
  • Ariane Chaudhuri,
  • Florin-Andrei Taran,
  • Markus Wallwiener,
  • Armin Bauer,
  • Diethelm Wallwiener,
  • Sara Yvonne Brucker,
  • Stephanie Wallwiener,
  • Andreas Hartkopf,
  • Tobias Engler

摘要

Background

Male breast cancer (BC) is a rare entity and represents a significant clinical challenge due to its late diagnosis and resulting poorer prognosis compared to female BC. As shown by prior studies, approximately 99% of male BC patients are hormone receptor-positive (HR +). This study aimed to evaluate the utilization and impact of adjuvant endocrine therapy (ET) in male early BC patients using a large German real-world claims dataset.

Patients and methods

Data were collected from a major German statutory health insurance provider (AOK Baden-Wuerttemberg) covering the period between January 1, 2010, and December 31, 2020. Male patients diagnosed with early BC who underwent breast surgery were included. ET use was determined by prescription records. The impact of ET on overall survival (OS) was assessed using univariable (log-rank) and multivariable (cox regression) analysis.

Results

Among 128 male early BC patients, 16% (n = 21) did not utilize adjuvant ET. On univariable analysis, ET was significantly associated with 5-year OS (74% with ET vs. 37% without ET; p < 0.0001). Multivariable analysis revealed ET use (Hazard Ratio [HR]: 0.31, 95% CI 0.14–0.69, p = 0.004) having a positive effect on OS, whereas age (HR: 1.04, 95% CI 1.00–1.09) and comorbidities (HR: 1.18, 95% CI 1.05–1.34, p = 0.007) were identified as negative predictive factors for OS.

Conclusion

A significant proportion of male patients with early BC does not use ET. However, the use of ET plays a key role in improving survival outcomes for male patients with early BC. Efforts to improve the use of ET, including patient education and management of side effects, are essential to optimize treatment outcomes.